Advanced search
Publication Cover
Immunotherapy Volume 14, 2022 - Issue 11
Submit an article Journal homepage
229
Views
0
CrossRef citations to date
0
Altmetric
Research Article

First-Line Chemoimmunotherapy Versus Chemotherapy in PD-L1-Negative Patients with Non-Small-Cell Lung Cancer

Daniele Mengato1 Hospital Pharmacy Department, Bolzano General Hospital, Bolzano, ItalyORCID Iconhttps://orcid.org/0000-0003-1374-1505
ORCID Icon,
Luca Cancanelli2 Hospital Pharmacy Department, Azienda Ulss 2 Marca Trevigiana, Treviso, ItalyORCID Iconhttps://orcid.org/0000-0002-6409-4195
ORCID Icon,
Melania Rivano3 Clinical Oncology Pharmacy Department, A. Businco, Cagliari, ItalyORCID Iconhttps://orcid.org/0000-0002-8541-539X
ORCID Icon,
Marco Chiumente4 Scientific Direction, Società Italiana di Farmacia Clinica e Terapia, Milan, ItalyCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-0943-6746
ORCID Icon,
Lorenzo Di Spazio5 Hospital Pharmacy Department, S.Chiara Hospital, Trento, ItalyORCID Iconhttps://orcid.org/0000-0002-1048-5166
ORCID Icon &
Andrea Messori6 HTA Unit, Regional Health Service, Florence, ItalyORCID Iconhttps://orcid.org/0000-0002-5829-107X
ORCID Icon
Pages 871-877 | Received 30 Jul 2021, Accepted 20 May 2022, Published online: 13 Jun 2022

References

  • Planchard D Popat S , KerrKet al. Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol.29(4), iv192–iv237 (2018).
  • Socinski MA , ObasajuC , GandaraDet al. Current and emergent therapy options for advanced squamous cell lung cancer. J. Thorac. Oncol.13(2), 165–183 (2018).
  • Brahmer J , ReckampKL , BaasPet al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N. Engl. J. Med.373(2), 123–135 (2015).
  • Rittmeyer A , BarlesiF , WaterkampDet al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a Phase 3, open-label, multicentre randomised controlled trial. Lancet389(10066), 255–265 (2017).
  • Herbst RS , BaasP , KimDWet al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet387(10027), 1540–1550 (2016).
  • Reck M , Rodríguez-AbreuD , RobinsonAGet al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N. Engl. J. Med.375(19), 1823–1833 (2016).
  • Gandhi L , Rodríguez-AbreuD , GadgeelSet al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N. Engl. J. Med.378(22), 2078–2092 (2018).
  • West H , McCleodM , HusseinMet al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMPOWER-130): a multicentre, randomised, open-label, Phase 3 trial. Lancet Oncol.20(7), 924–937 (2019).
  • Paz-Ares L , LuftA , VicenteDet al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N. Engl. J. Med.379(21), 2040–2051 (2018).
  • Jotte R , CappuzzoF , VynnychenkoIet al. Atezolizumab in combination with carboplatin and nab-paclitaxel in advanced squamous nsclc (impower-131): results from a randomized Phase III trial. J. Thorac. Oncol.15(8), 1351–1360 (2020).
  • Nishio M , BarlesiF , WestHet al. Atezolizumab plus chemotherapy for first-line treatment of nonsquamous nsclc: results from the randomized Phase 3 IMPOWER-132 trial. J. Thorac. Oncol.16(4), 653–664 (2021).
  • Hellmann MD , Paz-AresL , BernabeCaro Ret al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N. Engl. J. Med.381(21), 2020–2031 (2019).
  • WebPlotDigitizer. https://automeris.io/WebPlotDigitizer
  • Messori A . Analysis of survival curves: a compendium of methods for managing restricted mean survival time and mean lifetime survival in the context of a Bayesian network meta-analysis. Open Science Framework10.17605/OSF.IO/4MDXR (2021). https://osf.io/3g59j/
  • Messori A , BartoliL , ChiumenteMet al. The restricted mean survival time as a tool for ranking comparative outcomes in a narrative review that evaluates a network of randomized trials: an example based on PCSK9 inhibitors. Am. J. Cardiovasc. Drugs21(3), 349–354 (2021).
  • Messori A . The advantages of restricted mean survival time in analysing Kaplan-Meier survival curves: analysis of 55 articles published in the last 12 months. Open Science Framework10.17605/OSF.IO/BHQNY (2020). https://osf.io/bvqnk/
  • Messori A . Eight major international journals have recently published a paper to highlight the methodological advantages of the restricted mean survival time. Open Science Framework10.17605/OSF.IO/DY3UH (2020). https://osf.io/3gj96/
  • Pathak R , DeLima Lopes G , YuHet al. Comparative efficacy of chemoimmunotherapy versus immunotherapy for advanced non-small cell lung cancer: a network meta-analysis of randomized trials. Cancer127(5), 709–719 (2021).
  • Herbst R , JassemJ , AbogunrinSet al. A network meta-analysis of cancer immunotherapies versus chemotherapy for first-line treatment of patients with non-small cell lung cancer and high programmed death-ligand 1 expression. Front. Oncol.11, 676732 (2021).
  • Rizvi NA , ChoBC , ReinmuthNet al. Durvalumab with or without tremelimumab vs standard chemotherapy in first-line treatment of metastatic non-small cell lung cancer: the MYSTIC Phase 3 randomized clinical trial. JAMA Oncol.6(5), 661–674 (2020).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.